Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Upgrades Cerence to Outperform, Announces $110 Price Target

RBC Capital analyst Joseph Spak upgrades Cerence (NASDAQ:CRNC) from Sector Perform to Outperform and announces $110 price target.

byBenzinga Newsdesk

October 6, 2021

1 minute read

RBC Capital analyst Joseph Spak upgrades Cerence (NASDAQ:CRNC) from Sector Perform to Outperform and announces $110 price target.

Analyst Ratings

Analyst Ratings For Square

By Benzinga Insights

October 12, 12:32 PM

Within the last quarter, Square (NYSE:SQ) has observed the following analyst ratings:

Morgan Stanley Maintains Overweight on Endava, Raises Price Target to $110

By Benzinga Newsdesk

January 27, 11:02 AM

Morgan Stanley analyst James Faucette maintains Endava (NYSE:DAVA) with a Overweight and raises the price target from $95 to $110.

DAVA

Agilent To $165? These Analysts Boost Price Targets On The Lab Tools Firm Following Upbeat Q3 Earnings

By Lisa Levin

November 22, 10:17 AM

Agilent Technologies, Inc. (NYSE: A) reported better-than-expected Q4 results.

Moving iMage Technologies Announces Receipt Of Multiple Purchase Orders For Equipment Upgrades

By Bill Haddad

December 7, 7:16 AM

Moving iMage Technologies (NYSE:MITQ) ("MiT"), a leading digital cinema technology company, today announced it recently received three procurement contracts for upgrades. These purchase orders are part of a

MITQ

RBC Capital Upgrades Cerence to Outperform, Announces $110 Price Target

Related Posts

Analyst Ratings For Square

Morgan Stanley Maintains Overweight on Endava, Raises Price Target to $110

Agilent To $165? These Analysts Boost Price Targets On The Lab Tools Firm Following Upbeat Q3 Earnings

Moving iMage Technologies Announces Receipt Of Multiple Purchase Orders For Equipment Upgrades